122535-03-9

Basic information

• Product Name: ethyl furo[3,2-b]pyridine-6-carboxylate
• Synonyms: ethyl furo[3,2-b]pyridine-6-carboxylate;Furo[3,2-b]pyridine-6-carboxylic acid ethyl ester;Ethyl Furo[3,2-B]Pyridine-6-Carboxylate(WX618543)
• CAS NO: 122535-03-9
• Molecular Formula: C10H9NO3
• Molecular Weight: 191.18336
• EINECS: -0
• Mol File: 122535-03-9.mol

Chemical Properties

• Melting Point: 63-65 °C(Solv: hexane (110-54-3))
• Boiling Point: 264.3±20.0 °C(Predicted)
• Appearance: /
• Density: 1.241±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.09±0.40(Predicted)
• CAS DataBase Reference: ethyl furo[3,2-b]pyridine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl furo[3,2-b]pyridine-6-carboxylate(122535-03-9)
• EPA Substance Registry System: ethyl furo[3,2-b]pyridine-6-carboxylate(122535-03-9)

Safety Data

• Hazardous Substances Data: 122535-03-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl furo[3,2-b]pyridine-6-carboxylate is used as a building block for the development of new drugs and pharmaceuticals. Its heterocyclic structure and carboxylate functional group contribute to its potential as a versatile component in the synthesis of bioactive compounds with therapeutic properties.
Used in Drug Discovery:
Ethyl furo[3,2-b]pyridine-6-carboxylate is employed as a starting material in drug discovery processes. Its unique structure and functional group provide opportunities for chemical modifications and optimization, leading to the development of novel therapeutic agents with improved efficacy and selectivity.
Used in Medicinal Chemistry Research:
Ethyl furo[3,2-b]pyridine-6-carboxylate serves as a valuable research tool in medicinal chemistry. Its heterocyclic framework and carboxylate group enable the exploration of structure-activity relationships and the design of new chemical entities with potential therapeutic applications.

Upstream product

• 59288-40-3 ethyl 5-hydroxy-6-iodo-3-pyridinecarboxylate 
• 59288-38-9 ethyl 5-hydroxy-3-pyridinecarboxylate 
• 27828-71-3 5-hydroxynicotinic acid 
• 80370-42-9 ethyl 2-formyl-3-oxopropanoate 
• 56267-48-2 N-(3-furyl)carbamic acid tert-butyl ester 

Relevant articles and documents

Synthesis method for 4-(tert-butoxycarbonyl) octahydrofuro[3,2-b] pyridine-6-carboxylic acid

The present incention relates to a synthesis method for 4-(tert-butoxycarbonyl) octahydrofuro[3,2-b] pyridine-6-carboxylic acid, and mainly solves the technical problem of no synthesis method suitable for industrialization at present. The synthesis method comprises six steps: first esterifying a compound 1 to obtain a compound 2; then performing iodination to produce a compound 3; acetylating the compound 3 to obtain a compound 4; then performing coupling to obtain a compound 5; performing cyclization to obtain a compound 6; performing hydrogenation to obtain a compound 7, then reacting with Boc anhydride to obtain a compound 8; and performing hydrogenation to obtain a final compound 9. The reaction formula is shown in the description.

Identification of MK-944a: A second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors

Recent results from human clinical trials have established the critical role of HIV protease inhibitors in the treatment of acquired immune-deficiency syndrome (AIDS). However, the emergence of viral resistance, demanding treatment protocols, and adverse side effects have exposed the urgent need for a second generation of HIV protease inhibitors. The continued exploration of our hydroxylaminepentanamide (HAPA) transition-state isostere series of HIV protease inhibitors, which initially resulted in the identification of Crixivan (indinavir sulfate, MK-639, L-735,524), has now yielded MK-944a (L-756,423). This compound is potent, is selective, and competitively inhibits HIV-1 PR with a K(i) value of 0.049 nM. It stops the spread of the HIV(IIIb)-infected MT4 lymphoid cells at 25.0-50.0 nM, even in the presence of α1 acid glycoprotein, human serum albumin, normal human serum, or fetal bovine serum. MK-944a has a longer half-life in several animal models (rats, dogs, and monkeys) than indinavir sulfate and is currently in advanced human clinical trials.

Furopyridine sulfonamides and their opthalmological compositions

Furopyridine sulfonamides are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure and disorders associated therewith such as glaucoma.